Tarsus Pharmaceuticals, Inc. (TARS) financials: revenue, earnings and cash flow
Fiscal 2018–2025 + TTM · from SEC filings · data as of November 16, 2026
Summary
Net income in fiscal 2025 was -$66M, a net margin of -14.7%; the best year in this period was 2018 with -$1M.
Over the twelve months to September 30, 2026, revenue was $682M and net income -$702M.
Free cash flow was -$22M in fiscal 2025 and positive in 1 of the 8 years shown.
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $682M | $451M | $183M | $17M | $26M | $57M | $0 | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Operating income | -$696M | -$71M | -$121M | -$143M | -$63M | -$12M | -$27M | -$4M | — |
| Net income | -$702M | -$66M | -$116M | -$136M | -$62M | -$14M | -$27M | -$5M | -$1M |
| EPS (diluted) | $-15.86 | $-1.59 | $-3.07 | $-4.62 | $-2.52 | $-0.67 | $-4.32 | $-1.98 | — |
| R&D | $116M | $64M | $53M | $50M | $43M | $42M | $19M | $3M | — |
| Revenue growth | — | +146.7% | +948.6% | −32.4% | −54.7% | — | — | — | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $50M | -$12M | -$83M | -$117M | -$49M | $4M | -$21M | -$4M | — |
| Capital spending | -$17M | -$10M | -$2M | -$2M | -$506000 | -$586000 | -$456000 | -$175000 | — |
| Free cash flow | $32M | -$22M | -$85M | -$119M | -$50M | $3M | -$22M | -$4M | — |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $67M | $42M | $28M | $20M | $13M | $8M | $839000 | $18000 | — |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $417M | $291M | $227M | $217M | $172M | $168M | $58M | $2M |
| Debt | — | $83M | $72M | $32M | $20M | $1M | $831000 | $164000 | — |
| Equity | — | $343M | $225M | $197M | $193M | $167M | $166M | -$6M | -$1M |
| Total assets | — | $562M | $377M | $265M | $228M | $179M | $172M | $58M | — |
| Shares (diluted) | 46M | 42M | 38M | 29M | 25M | 21M | 6M | 2M | — |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | — | — |
| Operating margin | -102.0% | -15.7% | -65.9% | -820.5% | -242.9% | -21.3% | — | — | — |
| Net margin | -102.9% | -14.7% | -63.2% | -778.9% | -240.5% | -24.2% | — | — | — |
| FCF margin | 4.8% | -4.9% | -46.2% | -682.0% | -191.9% | 5.5% | — | — | — |
| ROIC | — | -13.2% | -40.6% | -62.6% | -29.4% | -5.7% | -12.8% | — | — |
| ROE | — | -19.3% | -51.5% | -69.0% | -32.2% | -8.3% | -16.2% | 77.8% | 97.4% |
Frequently asked questions
What is Tarsus Pharmaceuticals’s annual revenue?
$451M in fiscal 2025 and $682M over the twelve months to September 30, 2026.
How much profit does Tarsus Pharmaceuticals make?
Net income was -$66M in fiscal 2025 (net margin -14.7%).
Is Tarsus Pharmaceuticals’s revenue growing?
Yes: revenue rose 146.7% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.